Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$210MCash on Hand
15.4mo Cash Runway
Follow PROK by emailGet an email when PROK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PROK, unsubscribe in one click. Privacy
📣 What PROK Says Is Next
Q1 2027 · “Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by an acceleration in patient recruitment in mid-2026; the confirmatory endpoint (composite time-to-event) topline readout is expected in 2H 2029 American Society of Nephrology (ASN) Kidney Week 2026”
Company press release, Nov 12, 2026 · SEC filing
Q2 2027 · “On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027; the efficacy analysis set is expected to include approximately 320 patients”
Company press release, Nov 12, 2026 · SEC filing
Q1 2027 · “Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by accelerated patient recruitment in mid-2026”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Financing ProKidney filed a prospectus for an at-the-market offering of up to $200,000,000 of Class A common stock through Jefferies as sales agent, with commissions up to 3.0% of gross proceeds. Shares last traded at $1.13 on Nasdaq on November 11, 2026. Form 424B5 · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: cash, equivalents and marketable securities of $141.9 million, R&D expenses of $40.8 million, and G&A of $13.1 million. Cash is expected to support operations into mid-2027. PROACT 1 eGFR slope topline results remain on track for Q2 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Earnings ProKidney reported cash, cash equivalents and marketable securities of $141.9 million as of September 30, 2026, and updated its investor presentation, which says current cash supports operating plans into mid-2027. The Phase 3 PROACT 1 topline readout is expected in Q2 2027. Form 8-K · SEC filing · Press release
Oct 29, 2026 ·
Financing ProKidney filed a shelf registration statement to sell up to $650,000,000 of Class A common stock, preferred stock, debt securities, warrants, rights or units from time to time. A $200,000,000 portion is covered by an at-the-market sales agreement with Jefferies LLC. Form S-3 · SEC filing
Oct 29, 2026 ·
Financing ProKidney entered an open market sales agreement with Jefferies LLC to sell Class A common stock, up to $200,000,000 aggregate offering price, with the Sales Agent receiving up to 3.0% of gross proceeds. Sales depend on effectiveness of a Form S-3 shelf registration filed October 29, 2026. Form 8-K · SEC filing
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 10, 2026 ·
Earnings Reported Q2 2026 results: completed enrollment for the ~320-patient PROACT 1 accelerated approval analysis, with topline eGFR slope results expected Q2 2027. Cash, equivalents and marketable securities were $181.6 million, funding operations into mid-2027. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2028 · N/A · Recruiting · A Long-Term Follow-Up Study of Participants Exposed to REACT Registry primary completion date, not a results date
Dec 2029 · Phase 3 · Active Trial · Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease Registry primary completion date, not a results date
May 2030 · N/A · Enrolling · Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PROK holds $210M in cash and short-term investments (as of Jun 30, 2026) and burns about $41M/quarter from operations,
an estimated runway of 15.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:48 · Elevated
Cash runway 15 months +18
ATM program on file since Oct 2026 +15
Shelf registration (S-3, Oct 2026) +10
Going-concern doubt in the latest 10-Q +15These matters raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Raised after last reported balance sheet (Nov 2026) -10
Recent financing filings on SEC EDGAR:
Nov 12, 2026 · Registered direct / best-efforts offering · 424B5
Oct 29, 2026 · Shelf registration with ATM program, up to $200M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PROK and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.